RSS
SIGN IN
AI radiology tools are closest to full autonomy, but the FDA's regulatory framework still assumes human-in-the-loop oversight.
True if FDA grants approval for an AI system to make diagnostic decisions without mandatory physician review.
Multiple AI radiology systems outperforming human readers
FDA signaling openness to adaptive frameworks with 500+ cleared devices
Massive cost pressure on healthcare
NEW CRITICAL: AI-designed drug zasocitinib in Phase III trials showing FDA acceptance of autonomous AI decisions
173 AI drug programs in clinical development indicating mature regulatory pathways
Analysts predict 60% probability of first approval by 2026-2027
Major pharma investments like Eli Lilly's $2.75B AI deal demonstrate industry confidence
Liability frameworks don't exist yet
AMA lobbying against removal of physician oversight
Current approvals still require human oversight for final decisions
Drug discovery approval pathway differs significantly from diagnostic tool approval - drugs go through extensive clinical trials while diagnostics face different regulatory frameworks
Regulatory precedent in drug discovery doesn't automatically translate to autonomous diagnostic tool approval